OC METRO CALENDAR

  • October 2014
    SuMoTuWeThFrSa
    2829301234
    567891011
    12131415161718
    19202122232425
    2627282930311
    2345678
Add an event

MEDICAL RESEARCH
Untitled Page Published: May 14, 2009 10:18 AM





Oxygen Biotherapeutics contracts with U.S. Navy, continued ...

The Navy and the Virginia Commonwealth University Reanimation Shock Center, Oxygen's primary research partner, have a $3.8 million budget for the study of perfluorocarbon therapeutic oxygen carriers. It's welcome news for the company, which doesn't have the funding itself, says Stern.

There is no proven adjunct therapy – or treatments used in conjunction with the primary one – for decompression sickness and arterial gas embolism, he continues. But if the research is met with success and the Navy gets FDA approval, Oxygen could have the option to license the rights from the findings.

Oxygen Biotherapeutics is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and defense medicine.

<< PREVIOUS PAGE


Related headlines
UC Irvine banks $45 million for infectious disease research
NIH: Masimo's SpCo may gauge asthma severity in kids
May is Huntington's Disease Awareness month
UC Irvine Medical Center lands stroke therapy center designation